title: Is there a rationale for antiplatelet therapy in acute heart failure?
authors.affiliation: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mentz
authors.forename: Valentina
authors.initials: V
authors.lastname: Lazzarini
authors.forename: Mona
authors.initials: M
authors.lastname: Fiuzat
authors.forename: Marco
authors.initials: M
authors.lastname: Metra
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: G Michael
authors.initials: GM
authors.lastname: Felker
mesh_terms: D000208:Acute Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology*; D006487:Hemostasis; D006801:Humans; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D014336:Troponin / Q000097:blood
chemical_list: D010975:Platelet Aggregation Inhibitors; D014336:Troponin
keywords: acute heart failure; antiplatelet therapy; platelet activation